Table 3.

Primary and Secondary Endpoints Changes Between Before and 3 Months After IA Therapy

Parameters	Combined A+D
	Number of patients	Change for 3 months after IA									P values
Echocardiographic LVEF (%)a	39	23.8 ± 1.3 to 25.9 ± 1.3									0.0015
Trend analysis of Echocardiographic LVEFb	36	Improvement: eight patients (22%),									–
		Unchanged:27 patients (75%),
		Aggravation:one patient (3%)
Radionuclide LVEF (%)c	39	20.8 ± 1.1 to 21.9 ± 1.3									0.0605
Cardiothoracic ratio (%)	40	57.3 ± 1.2 to 55.9 ± 1.2									0.001
VO2max (mL/min/kg)d	15	12.3 ± 1.2 → 16.0 ± 1.8									0.0064
NYHA class N (%)	40	IV	:	2	→	1	−3%				<0.0001
		III	:	33	→	18	−45%	Improvement:	21	−52%
		II	:	4	→	15	−37%	unchanged:	18	−45%
		II	:	1	→	5	−12%	Aggravation:	1	−3%
		I	:	0	→	1	−3%
SAS (METs)	40	3.4 ± 0.2 → 3.9 ± 0.2									0.0022
6‐minute walk distance (m)	40	359 ± 20 to 390 ± 19									0.005
BNP (pg/mL)	40	426 ± 84 to 393 ± 82									0.4759
ANP (pg/mL)	40	172 ± 24 to 163 ± 27									0.5261

The data for changes in the 3 months after IA therapy in the IA group (A period) and the delay group (D period) were combined.

^aData were not obtained in one patient.

^bThe regression line was constructed using five LVEF values during the 3 months, and the slope of the regression line more than +5% or less than −5% for the period was defined as improvement or aggravation, respectively. Data missing in three patients.

^cData missing in one patient.

^dOnly patients who were able to undergo cardiopulmonary exercise testing.

ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; METs, metabolic equivalents; NYHA, New York Heart Association; SAS, specific activity scale; VO₂ max, maximal oxygen consumption.